- Home
- ANAB vs NBR Comparison
ANAB vs NBR Comparison
Compare ANAB & NBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANAB | NBR |
|---|---|---|
| Founded | 2005 | 1952 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ANAB | NBR |
|---|---|---|
| Price | $50.91 | $80.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 7 |
| Target Price | $71.67 | ★ $75.00 |
| AVG Volume (30 Days) | ★ 469.9K | 189.5K |
| Earning Date | 05-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.02 | ★ 177.74 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | $3.65 |
| Revenue Next Year | $52.14 | $4.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $23.15 | $36.66 |
| 52 Week High | $73.30 | $112.90 |
Technical Indicators
Market Signals| Indicator | ANAB | NBR |
|---|---|---|
| Relative Strength Index (RSI) | 34.85 | 34.79 |
| Support Level | $50.09 | $75.44 |
| Resistance Level | $51.67 | $85.30 |
| Average True Range (ATR) | 2.45 | 3.31 |
| MACD | -0.41 | -1.03 |
| Stochastic Oscillator | 16.64 | 4.59 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.